Drug Profile
Meningococcal vaccine group B conjugate - Baxter International
Alternative Names: NeisVac-BLatest Information Update: 01 Apr 2011
Price :
$50
*
At a glance
- Originator Baxter International
- Class Meningococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Meningococcal group B infections
Most Recent Events
- 13 Aug 2002 Phase-II clinical trials in Meningococcal group B infections in Belgium (Parenteral)
- 28 Apr 2001 Phase-I clinical trials for Meningococcal group B infections in Belgium (Unknown route)
- 27 Jun 2000 North American Vaccine has been acquired by and merged into Baxter International